Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

Type
Private
HQ
San Francisco, US
Founded
2013
Alector was founded in 2013 and is headquartered in San Francisco, US
Report incorrect company information

Key People/Management at Alector

Arnon Rosenthal

Arnon Rosenthal

Chief Executive Officer
Robert paul

Robert paul

Chief Medical Officer
Robert king

Robert king

Chief Development Officer
Sabah Oney

Sabah Oney

VP of Business Development
Tina Schwabe

Tina Schwabe

Head of Immuno-Neurology
Hua Long

Hua Long

Head of Immuno-Oncology
Show more

Alector Office Locations

Alector has offices in South San Francisco and San Francisco
San Francisco, US (HQ)
953 Indiana St
Show all (2)
Report incorrect company information

Alector Financials and Metrics

Summary Metrics

Founding Date

2013

Total Funding

$61.5 m

Latest funding size

$29.50 m

Time since last funding

2 years ago

Investors

Alector's latest funding round in January 2016 was reported to be $29.5 m. In total, Alector has raised $61.5 m
Report incorrect company information